Everything below concerns elevated plus maze. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-06. Numbers and descriptions here follow the published literature rather than marketing material.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
| Property | Value | Notes |
|---|---|---|
| Typical purity report | 95% or higher by HPLC | Area percentage at 214 nm |
| Identity confirmation | Mass spectrometry | Electrospray or MALDI |
| Powder storage | -20 C, desiccated | Protect from light |
| Solution storage | 2-8 C short term | Freeze aliquots for longer |
| Quality document | Certificate of analysis | States method and value |
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
==== Feud with Vince McMahon (1998–1999) ==== After Bret Hart's controversial departure for WCW, Austin and Michaels were the top stars in the company. Austin won the 1998 Royal Rumble, lastly eliminating The Rock. The next night on Raw, Austin interrupted Vince McMahon in his presentation of Mike Tyson, who was making a special appearance, over the objection of McMahon referring to Tyson as "the baddest man on the planet". Austin insulted Tyson by flipping him off, which led to Tyson shoving Austin much to McMahon's embarrassment, who began publicly to disapprove of the prospect of Austin as his champion. Tyson was later announced as "the special enforcer" for the main event at WrestleMania XIV, and aligned himself with Michaels's stable D-Generation X (DX). This led to Austin's WWF Championship match against Michaels at WrestleMania XIV, which he won with help from Tyson, who turned on DX by making the deciding three-count against Michaels and later hit him with his knock-out punch. This was Michaels's last match until 2002 as he had suffered two legitimate herniated discs and another completely crushed at the hands of The Undertaker in a casket match at the Royal Rumble. With Michaels's absence and Austin winning the WWF Championship, the "Austin Era" was ushered in.
family operates as a social unit, with social and business functions merged; leadership positions down to middle management are kinship based; the higher the position, the closer the kinship relationship; group assigns leadership positions to a central group of family members, including fictive god-parental relationship reinforcement; the leadership group are assigned to legal or illegal enterprises, but not both; and, transfer of money, from legal and illegal business, and back to illegal business is by individuals, not companies. Strong family ties are derived from the traditions of southern Italy, where family rather than the church or state is the basis of social order and morality.
2011: Icon acquired Oxford Outcomes, an international health outcomes consultancy and Firecrest Clinical, a technology provider specialising in site performance and study management 2012: Icon acquired PriceSpective, a global value strategy consultancy and Chinese CRO, BeijingWits 2013: Icon acquired staffing and FSP providers, ClinForce and Assent and Akos, an EU provider of pharmacovigilance and drug safety services 2014: Icon acquired Aptiv Solutions, a market leader in adaptive trial design and execution 2015: Icon acquired MediMedia Pharma Solutions to enhance market access and scientific communications capabilities, and PMG Research Inc., an integrated network of clinical research sites in the US 2016: Icon acquired Clinical Research Management Inc., to extend its presence in the government-sponsored research market 2017: Icon acquired MAPI Group, thereby becoming the world's second-largest provider of late-phase services 2019: Icon acquired Symphony Clinical Research, a leading provider of at-home patient services and site-support services; MediNova, an integrated network of clinical research sites across EMEA; and MolecularMD, to enhance its laboratory offerings in molecular diagnostic testing and immunohistochemistry 2020: Icon acquired MedPass International, a leading European medical device CRO, regulatory and reimbursement consultancy 2021: Icon acquired PRA Health Sciences, a competitor offering clinical research services, for US$12 billion.
Sources: en.wikipedia.org
== History == HFAP was established in 1943 by the American Osteopathic Association (AOA), and began surveying hospitals in 1945. Initially, HFAP provided osteopathic hospitals with accreditation ensuring osteopathic residents received appropriate training. In the mid-1960s the United States Congress decided that accredited hospitals would meet conditions set for participation, and thus automatically participated in newly established Medicare and Medicaid programs. HFAP quickly applied for and was granted said status in 1965. By 2012, HFAP accredited about 214 hospitals in the US. In 2015, ownership of HFAP moved from the AOA to the Accreditation Association for Hospitals/Health Systems (AAHHS).
In cosmetic applications, botulinum toxin is considered relatively safe and effective for reduction of facial wrinkles, especially in the uppermost third of the face. Commercial forms are marketed under the brand names Botox Cosmetic/Vistabel from Allergan, Dysport/Azzalure from Galderma and Ipsen, Xeomin/Bocouture from Merz, Jeuveau/Nuceiva from Evolus, manufactured by Daewoong in South Korea. The effects of botulinum toxin injections for glabellar lines ("11's lines" between the eyes) typically last two to four months and in some cases, product-dependent, with some patients experiencing a longer duration of effect of up to six months or longer. Injection of botulinum toxin into the muscles under facial wrinkles causes relaxation of those muscles, resulting in the smoothing of the overlying skin. Smoothing of wrinkles is usually visible three to five days after injection, with maximum effect typically a week following injection. Muscles can be treated repeatedly to maintain the smoothed appearance. DaxibotulinumtoxinA (Daxxify) was approved for medical use in the United States in September 2022. It is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines. DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent. The FDA approved daxibotulinumtoxinA based on evidence from two clinical trials (Studies GL-1 and GL-2), of 609 adults with moderate to severe glabellar lines. The trials were conducted at 30 sites in the United States and Canada.
=== Korean === In South Korea, soy sauces or ganjang (간장, "seasoning sauce") can be roughly split into two categories: hansik ganjang ('Korean-style soy sauce') and gaeryang ganjang ('modernized soy sauce'). The term ganjang can also refer to non-soy-based salty condiments, such as eo-ganjang fish sauce.
Sources: en.wikipedia.org
Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.
Dry powder is kept frozen, desiccated, and shielded from light. Dissolved material is aliquoted and frozen to limit freeze-thaw cycles. Short-term refrigerated storage is common for working solutions.
Russia registers it as a prescription nasal product. Most other markets classify it as a research chemical with no approved medical use. Oversight of purity and labeling is consequently minimal in those markets.
Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.